{"sequenceId":"845362163606","id":"34207110105","language":"English","title":"Ultragenyx Pharmaceutical Inc (RARE) Expected to Announce Earnings of -$2.13 Per Share","content":"Wall Street analysts expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to post earnings per share (EPS) of ($2.13) for the current quarter, Zacks Investment Research reports. Ten analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings. The lowest EPS estimate is ($2.36) and the highest is ($1.92). Ultragenyx Pharmaceutical reported earnings of ($1.72) per share in the same quarter last year, which would indicate a negative year over year growth rate of 23.8%. The firm is expected to report its next earnings report  on Thursday, July 26th.    On average, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($5.32) per share for the current year, with EPS estimates ranging from ($7.31) to ($3.80). For the next financial year, analysts anticipate that the business will report earnings of ($6.88) per share, with EPS estimates ranging from ($8.71) to ($4.32). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Ultragenyx Pharmaceutical.    Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Monday, May 7th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.81. The business had revenue of $10.68 million for the quarter, compared to analysts’ expectations of $56.58 million. During the same period in the previous year, the business posted ($1.63) earnings per share.    A number of research firms have issued reports on RARE. BidaskClub downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, February 9th. Robert W. Baird  reissued a “buy” rating and issued a $70.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 23rd. ValuEngine raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, April 11th. JPMorgan Chase & Co.  reissued an “overweight” rating and issued a $66.00 target price (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 21st. Finally, Stifel Nicolaus  reissued a “buy” rating and issued a $74.00 target price (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 21st. One investment analyst  has rated the stock with a sell rating, four have issued  a hold rating, seventeen have assigned  a buy rating and one  has given a strong buy rating to the stock. The company  has an average rating of “Buy” and a consensus target price of $70.06.    Shares of RARE traded up $0.53 on Friday, reaching $73.73. 515,198 shares of the company’s stock traded hands, compared to its average volume of 542,621. The company has a market capitalization of $3.60 billion, a price-to-earnings ratio of -9.83 and a beta of 1.83. Ultragenyx Pharmaceutical has a 52-week low of $41.67 and a 52-week high of $74.94.    In other news, Director Matthew K. Fust sold 6,319 shares of Ultragenyx Pharmaceutical stock in a transaction on Wednesday, May 30th. The stock was sold at an average price of $72.00, for a total value of $454,968.00. Following the completion of the transaction, the director now directly owns 8,750 shares in the company, valued at $630,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website . Also, EVP Karah Herdman Parschauer sold 1,465 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, May 10th. The shares were sold at an average price of $60.00, for a total value of $87,900.00. The disclosure for this sale can be found here . Over the last quarter, insiders sold 20,784 shares of company stock valued at $1,455,078. 8.40% of the stock is owned by company insiders.    Hedge funds and other institutional investors have recently made changes to their positions in the company. Profund Advisors LLC boosted its stake in  Ultragenyx Pharmaceutical by 5.6% during the first quarter. Profund Advisors LLC now owns 16,653 shares of the biopharmaceutical company’s stock valued at $849,000 after buying an additional 889 shares during the period.  American Century Companies Inc. boosted its stake in  Ultragenyx Pharmaceutical by 2.8% during the first quarter. American Century Companies Inc. now owns 36,720 shares of the biopharmaceutical company’s stock valued at $1,872,000 after buying an additional 997 shares during the period.  Wells Fargo & Company MN boosted its stake in  Ultragenyx Pharmaceutical by 5.0% during the first quarter. Wells Fargo & Company MN now owns 24,200 shares of the biopharmaceutical company’s stock valued at $1,234,000 after buying an additional 1,149 shares during the period.  RMB Capital Management LLC boosted its stake in  Ultragenyx Pharmaceutical by 3.3% during the first quarter. RMB Capital Management LLC now owns 45,178 shares of the biopharmaceutical company’s stock valued at $2,304,000 after buying an additional 1,445 shares during the period.  Finally, Verity Asset Management Inc. boosted its stake in  Ultragenyx Pharmaceutical by 26.4% during the first quarter. Verity Asset Management Inc. now owns 7,245 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 1,512 shares during the period. Institutional investors own  95.47% of the company’s stock.    About Ultragenyx Pharmaceutical    Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.    Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)    For more information about research offerings from Zacks Investment Research, visit Zacks.com","contentWithMarkup":"Wall Street analysts expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to post earnings per share (EPS) of ($2.13) for the current quarter, Zacks Investment Research reports. Ten analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings. The lowest EPS estimate is ($2.36) and the highest is ($1.92). Ultragenyx Pharmaceutical reported earnings of ($1.72) per share in the same quarter last year, which would indicate a negative year over year growth rate of 23.8%. The firm is expected to report its next earnings report  on Thursday, July 26th.    On average, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($5.32) per share for the current year, with EPS estimates ranging from ($7.31) to ($3.80). For the next financial year, analysts anticipate that the business will report earnings of ($6.88) per share, with EPS estimates ranging from ($8.71) to ($4.32). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Ultragenyx Pharmaceutical.    Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Monday, May 7th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.81. The business had revenue of $10.68 million for the quarter, compared to analysts’ expectations of $56.58 million. During the same period in the previous year, the business posted ($1.63) earnings per share.    A number of research firms have issued reports on RARE. BidaskClub downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, February 9th. Robert W. Baird  reissued a “buy” rating and issued a $70.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 23rd. ValuEngine raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, April 11th. JPMorgan Chase & Co.  reissued an “overweight” rating and issued a $66.00 target price (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 21st. Finally, Stifel Nicolaus  reissued a “buy” rating and issued a $74.00 target price (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 21st. One investment analyst  has rated the stock with a sell rating, four have issued  a hold rating, seventeen have assigned  a buy rating and one  has given a strong buy rating to the stock. The company  has an average rating of “Buy” and a consensus target price of $70.06.    Shares of RARE traded up $0.53 on Friday, reaching $73.73. 515,198 shares of the company’s stock traded hands, compared to its average volume of 542,621. The company has a market capitalization of $3.60 billion, a price-to-earnings ratio of -9.83 and a beta of 1.83. Ultragenyx Pharmaceutical has a 52-week low of $41.67 and a 52-week high of $74.94.    In other news, Director Matthew K. Fust sold 6,319 shares of Ultragenyx Pharmaceutical stock in a transaction on Wednesday, May 30th. The stock was sold at an average price of $72.00, for a total value of $454,968.00. Following the completion of the transaction, the director now directly owns 8,750 shares in the company, valued at $630,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website . Also, EVP Karah Herdman Parschauer sold 1,465 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, May 10th. The shares were sold at an average price of $60.00, for a total value of $87,900.00. The disclosure for this sale can be found here . Over the last quarter, insiders sold 20,784 shares of company stock valued at $1,455,078. 8.40% of the stock is owned by company insiders.    Hedge funds and other institutional investors have recently made changes to their positions in the company. Profund Advisors LLC boosted its stake in  Ultragenyx Pharmaceutical by 5.6% during the first quarter. Profund Advisors LLC now owns 16,653 shares of the biopharmaceutical company’s stock valued at $849,000 after buying an additional 889 shares during the period.  American Century Companies Inc. boosted its stake in  Ultragenyx Pharmaceutical by 2.8% during the first quarter. American Century Companies Inc. now owns 36,720 shares of the biopharmaceutical company’s stock valued at $1,872,000 after buying an additional 997 shares during the period.  Wells Fargo & Company MN boosted its stake in  Ultragenyx Pharmaceutical by 5.0% during the first quarter. Wells Fargo & Company MN now owns 24,200 shares of the biopharmaceutical company’s stock valued at $1,234,000 after buying an additional 1,149 shares during the period.  RMB Capital Management LLC boosted its stake in  Ultragenyx Pharmaceutical by 3.3% during the first quarter. RMB Capital Management LLC now owns 45,178 shares of the biopharmaceutical company’s stock valued at $2,304,000 after buying an additional 1,445 shares during the period.  Finally, Verity Asset Management Inc. boosted its stake in  Ultragenyx Pharmaceutical by 26.4% during the first quarter. Verity Asset Management Inc. now owns 7,245 shares of the biopharmaceutical company’s stock valued at $369,000 after buying an additional 1,512 shares during the period. Institutional investors own  95.47% of the company’s stock.    About Ultragenyx Pharmaceutical    Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.    Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)    For more information about research offerings from Zacks Investment Research, visit Zacks.com","tags":[],"publishedDate":"2018-06-02T21:18:37Z","harvestDate":"2018-06-02T21:24:13Z","estimatedPublishedDate":"2018-06-02T21:18:37Z","url":"http://ct.moreover.com/?a=34207110105&p=1u0&v=1&x=aPbJbTAlBn3is6U4R5KGug","originalUrl":"https://zolmax.com/investing/ultragenyx-pharmaceutical-inc-rare-expected-to-announce-earnings-of-2-13-per-share/2277403.html","outboundUrls":["https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","http://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&Symbol=RARE","https://www.marketbeat.com/stocks/NASDAQ/RARE/","http://www.sec.gov/Archives/edgar/data/1397266/000120919118034278/xslF345X03/doc4.xml","http://www.sec.gov/Archives/edgar/data/1515673/000120919118029310/xslF345X03/doc4.xml","https://www.zacks.com/registration/pfp/?ALERT=zrmodule&ADID=AMERBMN_CONTENT_ZER&skip_rpt_name_check=skip_rpt_name_check&t=RARE"],"wordCount":"841","dataFormat":"text","duplicateGroupId":"34207089628","media":{"audio":[],"images":[{"url":"https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=RARE"},{"url":"https://www.marketbeat.com/logos/ultragenyx-pharmaceutical-inc-logo.jpg"}],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Pharma industry news","group":"Industry"},{"name":"Earnings news","group":"Finance"},{"name":"Stockwatch","group":"Finance"}],"companies":[{"name":"Ultragenyx Pharmaceutical Inc","symbol":"RARE","exchange":"NAS","isin":"US90400D1081","titleCount":1,"contentCount":22,"primary":true},{"name":"Ultragenyx Pharmaceutical Inc","symbol":"UP0","exchange":"FRA","isin":"US90400D1081","titleCount":1,"contentCount":22,"primary":true},{"name":"Ultragenyx Pharmaceutical Inc","symbol":"UP0","exchange":"STU","isin":"US90400D1081","titleCount":1,"contentCount":22,"primary":true},{"name":"The Century Co Ltd","symbol":"002420","exchange":"KRX","isin":"KR7002420008","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"STU","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"BER","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"MUN","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"HAM","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"DUS","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"FRA","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"SWX","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"ETR","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCNP","exchange":"PINX","isin":"US9497468879","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"NYS","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"SGO","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"MEX","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"LIM","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCO34","exchange":"BSP","isin":"BRWFCOBDR009","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"BUE","isin":"ARDEUT110434","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"HAN","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpV","exchange":"NYS","isin":"US94988U7303","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpR","exchange":"NYS","isin":"US9497464654","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpW","exchange":"NYS","isin":"US94988U7147","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpO","exchange":"NYS","isin":"US9497467210","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpY","exchange":"NYS","isin":"US94988U6560","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpN","exchange":"NYS","isin":"US9497467475","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpJ","exchange":"NYS","isin":"US9497468796","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpX","exchange":"NYS","isin":"US94988U6727","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpL","exchange":"NYS","isin":"US9497468044","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpP","exchange":"NYS","isin":"US9497466550","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpT","exchange":"NYS","isin":"US9497463664","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpQ","exchange":"NYS","isin":"US9497465560","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"WBO","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"CMC","exchange":"STU","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"CMC","exchange":"HAN","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"CMC","exchange":"MUN","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"CMC","exchange":"FRA","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"CMC","exchange":"DUS","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"CMC","exchange":"BER","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"CMC","exchange":"HAM","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"CMC","exchange":"ETR","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPM","exchange":"SWX","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPM","exchange":"NYS","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPM","exchange":"BSE","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPM","exchange":"SGO","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPM","exchange":"BUE","isin":"ARDEUT110244","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPM","exchange":"MEX","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPM","exchange":"WBO","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"0Q1F","exchange":"LTS","isin":"US46625H1005","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPMpB","exchange":"NYS","isin":"US48127A1613","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPMpH","exchange":"NYS","isin":"US48127V8274","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPMpG","exchange":"NYS","isin":"US48127X5427","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPMpA","exchange":"NYS","isin":"US46637G1242","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPMpE","exchange":"NYS","isin":"US4812467003","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPMpF","exchange":"NYS","isin":"US48127R4618","titleCount":0,"contentCount":1,"primary":false},{"name":"JPMorgan Chase & Co","symbol":"JPMC34","exchange":"BSP","isin":"BRJPMCBDR009","titleCount":0,"contentCount":1,"primary":false}],"author":{"name":"Alphonse Anthony","publishingPlatform":{}},"licenses":[{"name":"CLA"}],"source":{"name":"Zolmax News","homeUrl":"http://zolmax.com","category":"National","editorialRank":"3","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"379974975","name":"Zolmax News","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"0"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Standard","News"],"genre":"General"}},"es_id":86990293}